The peptide synthesis market encompasses the development, production, and commercialization of custom and commercial peptides for use in pharmaceuticals, research, diagnostics, nutraceuticals, and cosmetic applications.
Peptides short chains of amino acids are synthesized via solid-phase, liquid-phase, or hybrid-phase techniques, and are increasingly integral to targeted therapeutics, vaccine design, antimicrobial treatments, and hormonal therapies.
In 2025, the peptide synthesis market is projected to reach approximately USD 606.5 million, and is expected to grow to around USD 1,321.6 million by 2035, reflecting a Compound Annual Growth Rate (CAGR) of 8.1% over the forecast period.
Key Market Metrics
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 606.5 Million |
| Projected Market Size in 2035 | USD 1,321.6 Million |
| CAGR (2025 to 2035) | 8.1% |
Market expansion is being driven by the growing number of peptide-based drugs in the pipeline, the rise of personalized medicine, and the increasing use of synthetic peptides in oncology, metabolic disorders, infectious diseases, and biomarker discovery.
Explore FMI!
Book a free demo
North America is the largest region in the global peptide synthesis market and accounted for the greatest market share in 2022 with the highest contribution, especially in the USA, because of extensive R&D infrastructure activities and the rising prevalence of clinical trials and the increasing number of FDA drug approvals for peptide therapeutics.
Companies are investing in automated synthesizers, high-throughput purification systems and good manufacturing practice (GMP)-certified manufacturing. Oncology and metabolic peptide drugs have high growth, and large-scale CROs and CDMOs help the market.
In Europe, where Germany, Switzerland, the UK, and France are the most active market, primarily driven by biotech investment, academic partnerships, and behavioral transparency from the European Medicines Agency (EMA). Peptides have been in focus of the region with emphasis on green chemistry for peptide synthesis, increasing demand for injectables and biosimilars, and growing use of peptide-based cosmetics and dermatological applications.
The Asia-Pacific region should grow at the fastest growth rate, especially in China, India, South Korea, and Japan, where biosimilar development, low-cost synthesis capability, and pharmaceutical outsourcing are growing aggressively. The surge in health care expenditure, collaborations in the Biotech Park and, government support for post-COVID-19 peptide vaccine production have benefitted the region.
High Cost of Reagents, Scalability, and Purification Bottlenecks
Also, as unique amino acids, coupling reagents and resins are extremely expensive, high cost of raw materials is another critical challenge in the Peptide Synthesis Market, especially when dealing with complex or lengthy peptides. Moreover, the transition from lab to commercial manufacturing can be difficult to maintain on purity, yield, and consistency, particularly the therapeutic-grade peptides.
Since purification and characterization by HPLC and mass spectrometry are labor- and time-consuming, this leads to increased total production costs. Smaller CDMOs and research laboratories also face significant challenges with regulatory compliance (GMP/ICH guidelines) in peptide drug production.
Biopharma Growth, Custom Peptide Services, and Automated Synthesis Platforms
The sector shows robust growth, driven by rising needs for peptide-based drugs, vaccines, diagnostics and cosmeceuticals. More than 100 peptide drugs currently approved and others in clinical trials drive demand for custom, high-purity, and GMP-compliant peptide synthesis globally. SPPS and LPS technologies tend to become more advanced, enabled by automation, microwave-assisted synthesis, and artificial intelligence (AI)-empowered sequence optimization platforms. Large peptide libraries, cell-penetrating peptides, and conjugate peptides (ADC, PEGylated) are also gaining traction and drive demand in both academic research and pharmaceutical research industries.
The market experienced steady growth between 2020 to 2024, with a focus on COVID-19 peptide vaccine candidates, antimicrobial peptides, and immunomodulatory peptides. The expansion was driven by academic and pharmaceutical research, and innovation was concentrated on short-chain and medium-length peptides for therapeutic and diagnostic use.
Industrial-scale, affordable, green peptide synthesis based on flow technology, green solvents, and modular assembly automation are expected to be the market trends from 2025 to 2035. Further in offering demand for ultra-pure, custom-sequenced peptides will be driven by personalized medicine, vaccines for cancer, and treatment of rare diseases with peptide platforms.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Emphasis on GMP compliance for peptide drug manufacturers |
| Technology Innovations | Adoption of automated SPPS platforms, microwave-assisted synthesis |
| Market Adoption | Dominant in oncology, metabolic disorder research, and vaccine development |
| Sustainability Trends | Shift toward solvent recycling and improved coupling efficiency |
| Market Competition | Led by Bachem, Poly Peptide Group, Gen Script, Thermo Fisher, Merck KGaA |
| Consumer Trends | High demand for custom peptides for R&D and diagnostics |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Broader harmonization of global peptide API standards, including automated QC integration |
| Technology Innovations | Emergence of continuous flow synthesis, AI-based peptide design, and low-waste green chemistry systems |
| Market Adoption | Expansion into neurology, dermatology, anti-aging cosmetics, and precision immunotherapy |
| Sustainability Trends | Industry-wide adoption of eco-friendly reagents, zero-waste peptide production, and biodegradable resins |
| Market Competition | Entry of AI-powered peptide design firms, specialized CDMOs, and academic-industry spinouts |
| Consumer Trends | Increasing preference for therapeutic-grade peptides, smart delivery systems, and conjugated peptide platforms |
Market growth is attributed to factors like rising demand for peptide therapeutics, increasing biopharmaceutical R&D, and evoking application in cancer, metabolic disorders, and infectious diseases.
High expenditure on custom peptide synthesis service for vaccine development, specific drug delivery, and biomarker detection has been witnessed from academic institutes and Biotech Company. Growing accessibility to next-generation solid-phase synthesis technology and automated peptide synthesizers is helping to improve production scalability and speed of synthesis.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 8.5% |
The UK peptide synthesis market is growing due to increasing biomedical research, higher government investments in precision medicine and increasing collaborations between pharmaceutical companies and academic research laboratories.
Looking forward, North America is slated to be a key region offering robust peptide contract manufacturing infrastructure and witnessing surging demand for therapeutic and diagnostic peptides in both oncology and endocrinology applications. Exports prospects are further bolstered by custom peptide services and GMP-compliant manufacturing capabilities.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 7.9% |
The demand for EU peptide synthesis market is high in these regions, as Germany, France, and Switzerland are the leading countries across Europe. The increasing utilization of peptides in therapeutic vaccines, antimicrobial drugs, and hormone replacement therapy is driving demand.
EU-based CDMOs and biotechs are investing in sustainable synthesis technologies, green solvents, and continuous flow technology. This is allowing for cross border peptide development projects to become more feasible with regulations being harmonized within member states.
| Country | CAGR (2025 to 2035) |
|---|---|
| EU | 7.7% |
Peptide synthesis is currently aiding Japan's growth at a maintained growth rate due to the continuance of events like precision medicine, recent discoveries in biotech R&D, and utility as drugs in various metabolic and respiratory diseases.
Novel peptide analogs with improved bioavailability and stability are being developed by Japanese pharmaceutical companies. The country also encourages R&D on peptide nucleic acids (PNAs) and artificial vaccines, which has led to the growing demand and utilization of custom synthesis platforms.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 8.1% |
the company has grown and expanded in South Korea, with pharma products including monoclonal antibodies increasingly seen as a 'strategic priority' area while the country carries a strong production base for pharmaceuticals that produces 46% of the regions' peptide products.
Currently, there is an active development of peptides for dermatology skincare, anti-obesity, and oncology therapeutics. Government-sponsored biotech centers and cooperation between academia and industry drive the development of affordable scalable and high-purity synthetic peptides.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 8.3% |
| Capacity type | Market Share (2025) |
|---|---|
| Reagents | 46% |
The largest share is accounted for by reagents from a market value perspective with nearly 46% of the peptide synthesis market. With reagents providing the chemical backbone for peptide synthesis, the reagents segment has a central functional role to play in peptide synthesis at both research and industrial levels.
Their invaluable function ranges from safeguarding group agents, activating agents, solvents, and amino acid derivatives to coupling agents to allow elongation of peptide chains, in a controlled, high-fidelity manner. The Reagent segment, constantly evolving with newer techniques and supply due to high demand for synthetic peptides rising at an exponentially increasing rate in pharmaceutical, biotechnological and diagnostic industries is also a key force supporting the growth of the market.
The increase in peptide-based drugs and biologics has also highlighted the need for high-quality, high-purity reagents that can support the synthesis of longer and more complex peptides. Institution Research, CMOs, and pharma manufacturers are heavily reliant on GMP-compliant protocol specific reagents and those that are compliant with guidelines from regulatory agencies.
This is reflected in the increasing number of peptide sequenced requested, across cancer therapeutics, metabolic disorders, immunotherapy, and vaccine development.
Innovations in reagent design technology have also improved yield efficiency, reduced by-product generation and streamlined purification steps. The development of next-generation coupling reagents such as HBTU, HATU and PyBOP have allowed manufacturers to minimize reaction times and maximize the throughput of peptide synthesis protocols. Meanwhile, the greening of chemistry has also had an influence on reagent selection, where researchers often look for substitutes with reduced solvent use or reduced amounts of toxic waste generated during peptide synthesis.
This segment is one of the most characteristic as it has a direct effect on the quality of the final peptide product. In high-risk pharmaceutical applications, even minute levels of impurity introduced by reagents can endanger product safety and efficacy7. As a result, reagent suppliers have stepped up to provide ultra-pure, analytically verified products meeting strict pharmacopeial specifications.
Now you can get documentation from manufacturers which details residual solvent levels, heavy metal content, as well as batch-specific stability data -rebuttal to stability testing particularly for reagents used in cGMP production lines.
Geographically, the United States and Europe are leading the market for reagent consumption, which results from huge pharma R&D, biotech start-ups, and university-initiated peptide discovery programs present in these regions.
However, the demand is rising in the Asia-Pacific countries, primarily in China, India, and South Korea, where the production of peptide therapeutics and generics is expanding at a rapid pace. To address growing demand and reduce turnaround time, reagent firms have begun establishing localized supply chains and manufacturing facilities in these markets.
The reagent segment faces challenges even with strong growth, including fluctuations in raw material prices and the supply chain disruption factors highlighted during the COVID-19 pandemic. Suppliers responded by expanding their supply networks and investing in real-time inventory tracking technologies in order to maintain continuity of service.
These proactive steps have instilled confidence across end users and reaffirmed the importance of this part of the peptide synthesis ecosystem.
As at some point, the purpose in designing peptide drug candidates (e.g., historic short chains) is designed towards long and cyclized peptides in addition to peptide-drug conjugates, the synthesis protocols turn out to be extra challenging and these components will ultimately elevate the demand for professional reagents.
High-throughput reagent sets, automation-compliant reagents, and greener formulations will move more and more into the spotlight. The reagent segment is expected to maintain its dominance across the global market owing to its primary role in peptide synthesis and compatibility in both industrial and research processes.
| Technology type | Market Share (2025) |
|---|---|
| Solid-phase Peptide Synthesis | 63% |
The SPPS dominates peptide synthesis technology with approximately 63% market share. SPPS, first developed by Robert Bruce Merrifield in the 1960s and still considered the gold standard today, has continually revolutionized how peptides are manufactured with an approach that allows individual amino acids to be added in sequence and the resulting peptide chains to remain tethered to an insoluble resin.
Despite the emergence of many peptide synthesis strategies thereafter, none have matched SPPS for efficiency, scalability, or automation compatibility, making SPPS the methodology of choice for modern peptide synthesis in research, clinical and industrial laboratories.
Its unprecedented superiority is because SPPS can synthesize both short and long-chain peptides, including stubborn sequences that require complex modifications or rare amino acids. Because the elongating peptide is tethered to a solid medium, SPPS simplifies purification compared to solution-phase peptide synthesis, as excess reagents and by-products can simply be washed away.
Moreover, SPPS has the flexibility to be adapted for varying synthesis scales, capable of producing as little as microgram quantities in academic settings or scaled up to kilogram production for pharmaceutical use.
Drug discovery workflows commonly utilize SPPS. The speed and reproducibility of constructing large libraries of peptides from this automation capability is essential for screening of drug leads or active motifs. Automated high-throughput peptide synthesizers utilizing solid-phase peptide synthesis (SPPS) procedures can rapidly generate hundreds of peptides with various modifications, thereby increasing time-to-hit discovery in early stage research.
Innovation in technology in SPPS continues to push the limits in terms of both speed, purification, and yield. Additionally, microwave-assisted SPPS has allowed for reduced cycle times and improved coupling efficiency, especially for sequences bearing sterically challenging motifs or iterative sequences.
In addition, innovation of new resin types, such as PEG-based or low-loading polystyrene supports, can improve solubility and accessibility to the sequence, reducing side reactions and aggregation. Pre-packed columns or cartridges specifically designed for SPPS are widely available from many manufacturers, enabling even non-experienced users to perform effective synthesis-based protocols.
SPPS is widely utilized by the pharmaceutical industry for the manufacture of therapeutic peptides. As of 2024, there were over 80 FDA-approved peptide drugs, all synthesized by SPPS, and the list is still growing.
Therapeutic categories where peptides are particularly dense are oncology, endocrinology, and infectious diseases, and SPPS remains the most reliable platform to ensure reproducibility, batch-to-batch reproducibility, and regulatory compliance. When combined with analytical workhorses, such as LC-MS and MALDI-TOF, it enables real-time quality control, enabling cGMP-compliant synthetic processes.
While SPPS is better, it has many limitations. Environmental and workplace safety concerns arise from the high volumes of organic solvents used, e.g., DMF and DCM. Industry players are already looking into more sustainable solvent systems, resin recycling, and more solventless coupling protocols. Regulatory bodies, especially in Europe, are promoting green approaches to pharmaceuticals synthesis, encouraging improvements in the sustainability of SPPS-based manufacture.
In future, the SPPS market will further increase due to increasing prevalence of advanced and synthetic peptides such as cyclic peptides, stapled peptides, and peptide-drug conjugates. The need for metal-free chemical components, new advanced photo labile linkers, continuous flow systems, and automated solid-phase reactors will all work to further enhance the efficiency, environmental footprint, and commercial viability of SPPS.
The peptide synthesis market is witnessing robust growth on the back of rising applications in the fields of therapeutics, diagnostics, vaccine development, cosmetics, and research. Synthetic peptides are pivotal in the design of targeted therapies for cancer, metabolic diseases, infectious diseases, and autoimmune diseases.
Key market drivers include advancements in solid-phase synthesis (SPS), automation, custom peptide services, rising R&D in peptide-based drugs, and the growing use of peptides in biologics and biosimilar.
Market Share Analysis by Key Players
| Company/Organization Name | Estimated Market Share (%) |
|---|---|
| Bachem Holding AG | 18-22% |
| Thermo Fisher Scientific Inc. | 14-18% |
| Merck KGaA (Sigma-Aldrich) | 12-16% |
| GenScript Biotech Corporation | 10-14% |
| CEM Corporation | 8-12% |
| Others | 26-32% |
| Company/Organization Name | Key Offerings/Activities |
|---|---|
| Bachem Holding AG | In 2024, Bachem expanded its large-scale GMP peptide synthesis facilities in Switzerland and the USA, catering to pharma and biotech clients for injectable peptide therapeutics. |
| Thermo Fisher Scientific Inc. | As of 2025, Thermo Fisher introduced automated peptide synthesizers and custom peptide synthesis kits for academic, preclinical, and industrial users, enabling rapid turnaround and scale-up flexibility. |
| Merck KGaA (Sigma-Aldrich) | In 2023,Merck launched a new portfolio of ultra-pure synthetic peptides for cell signaling, epitope mapping, and therapeutic formulation, supporting bioscience and CRO labs globally. |
| GenScript Biotech Corporation | In 2023, GenScript enhanced its custom peptide service platform with AI-assisted design tools, stability optimization, and labeling options, targeting biotech startups and academic research institutes. |
| CEM Corporation | As of 2024, CEM launched its Liberty PRO™ Microwave Peptide Synthesizer, offering high-throughput peptide assembly with real-time monitoring, ideal for biopharma R&D and process development. |
Key Market Insights
Bachem Holding AG (18-22%)
Bachem is a global leader in GMP-grade peptide production, supplying bulk APIs and custom peptides for oncology, endocrinology, and rare disease therapeutics, with a strong focus on regulatory compliance and scalability.
Thermo Fisher Scientific Inc. (14-18%)
Thermo Fisher serves a broad customer base with modular peptide synthesis systems, purification kits, and standard peptide libraries, favored in drug discovery, academic R&D, and biotechnology.
Merck KGaA (Sigma-Aldrich) (12-16%)
Merck offers analytical- and research-grade peptides along with solid-phase reagents and resins, widely used in life science labs and biologics development, supported by a robust global distribution network.
GenScript Biotech Corporation (10-14%)
GenScript provides custom, modified, and fluorescent-tagged peptides with end-to-end synthesis and characterization, attracting CROs, biotech firms, and university labs working on functional peptide assays.
CEM Corporation (8-12%)
CEM specializes in automated and microwave-based synthesis systems, enabling high-speed peptide assembly with applications in high-throughput screening, personalized peptide vaccines, and novel biologics.
Other Key Players (26-32% Combined)
Numerous regional and specialized providers are driving innovation in sustainable synthesis, AI-driven design, and novel delivery formats, including:
The overall market size for peptide synthesis market was USD 606.5 million in 2025.
The peptide synthesis market is expected to reach USD 1,321.6 million in 2035.
Expanding use of peptides in drug development, rising demand in personalized medicine, and advancements in automated synthesis technologies will drive market growth.
The top 5 countries which drives the development of peptide synthesis market are USA, European Union, Japan, South Korea and UK.
Solid-phase peptide synthesis expected to grow to command significant share over the assessment period.
Protein Diagnostics Market Share, Size and Forecast 2025 to 2035
CGRP Inhibitors Market Trends - Growth, Demand & Forecast 2025 to 2035
Indolent Systemic Mastocytosis treatment Market Insights: Size, Trends & Forecast 2025 to 2035
Intraoperative Fluorescence Imaging Market Report - Demand, Trends & Industry Forecast 2025 to 2035
Lung Cancer PCR Panel Market Trends, Growth, Demand & Forecast 2025 to 2035
Polymyxin Resistance Testing Market Trends – Innovations & Growth 2025 to 2035
Peptide Synthesis Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
